Early Three-Dimensional Left Atrial and Right Ventricular Deformation changes during Immunotherapy and Targeted Cancer Therapy: A Prospective Cohort Study
This prospective cohort study of 45 cancer patients found that right ventricular and left atrial conduit deformation significantly declined within three months of starting immunotherapy or targeted therapy, though the absence of a control group prevents attributing these changes directly to treatment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer treatment has entered a new era where powerful drugs, known as immunotherapy and targeted therapy, help the body's own defenses fight tumors or block the specific signals that allow cancer to grow. These treatments have saved countless lives, but they come with a hidden cost: they can sometimes damage the heart. Doctors have long known that certain older chemotherapy drugs could weaken the main pumping chamber of the heart, the left ventricle. To catch this early, they now use a special ultrasound technique that measures how much the heart muscle stretches and squeezes, looking for tiny signs of trouble before the heart actually fails. However, the heart is a complex machine with four chambers, and the left ventricle is not the only one exposed to these drugs. The right ventricle, which pumps blood to the lungs, and the left atrium, which collects blood from the lungs, are also in the line of fire. Scientists have suspected these chambers might show signs of distress earlier than the main pump, but they lacked clear evidence because measuring them accurately is difficult and has rarely been done in patients receiving these modern cancer therapies.
A team of researchers in India set out to watch these specific parts of the heart in real time. They followed forty-five adults who were just starting a course of either immunotherapy or targeted therapy for various types of cancer. None of these patients had heart disease before they began treatment. The researchers used advanced ultrasound imaging to take detailed, three-dimensional pictures of the heart at the start of treatment, and then again at three months and six months. They focused on measuring how much the muscle fibers in the right ventricle and the left atrium could stretch and recoil, a process called deformation. They also tracked standard heart measurements, such as the size of the chambers and the pressure in the blood vessels, and kept a close watch on the heart's electrical rhythm to see if any new irregularities appeared.
The results revealed a clear pattern of change that happened quickly. Within the first three months of starting therapy, the ability of the right ventricle to stretch and squeeze began to decline significantly. The muscle fibers in this chamber, which normally stretch to about twenty-five percent of their length, lost that capacity, dropping to around twenty-two percent by the three-month mark and staying there through the six-month visit. Similarly, the left atrium, which acts as a passive waiting room for blood coming from the lungs, showed a sharp drop in its ability to let blood flow through it smoothly. This passive flow function, known as conduit strain, fell from an average of twenty percent to fifteen percent. Interestingly, the active squeezing part of the left atrium, which helps push blood into the main pump, did not change at all. The researchers found that these changes in the right ventricle and the passive part of the left atrium happened in parallel with other signs that the heart was under stress, such as rising blood pressure in the lungs and a slight increase in the size of the right ventricle.
The study also looked at whether these early changes in heart muscle stretching could predict who would develop a new heart rhythm problem. Over the six months, half of the patients who started with a normal heart rhythm developed a new irregularity, most commonly a fast heart rate. However, the researchers found no link between the amount of stretching loss in the heart muscle and who got these rhythm problems. A patient whose heart muscle stretched less than others was no more likely to develop a fast heart rate than a patient whose heart stretched normally. The only faint signal was that patients who eventually developed a rhythm issue had started with slightly lower stretching numbers in the left atrium, but this difference was small and could easily have happened by chance.
Crucially, the researchers were careful to explain what their findings do not prove. Because they did not have a group of patients to compare against—people with cancer who did not receive these specific drugs—they cannot say for certain that the drugs caused the heart changes. It is possible that the cancer itself, the stress of the illness, or other factors like anemia or dehydration contributed to the decline. Furthermore, the study did not measure the main left ventricle, so they cannot say if these changes in the right ventricle and left atrium happen before the main pump starts to fail. What they did establish is that these specific parts of the heart do change measurably during the first six months of treatment, with most of the decline happening in the first three months. The changes suggest the heart is struggling with increased pressure and stiffness, but without a control group, the exact cause remains a question. The study highlights that while modern heart monitoring can see these subtle shifts, we still need more research to understand if watching these specific chambers can help doctors predict serious heart trouble or rhythm problems before they become dangerous.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.